NCT03934502 is a Phase 1 clinical trial of Evobrutinib in Healthy, sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany.

What drugs are being tested in NCT03934502?

Interventions in NCT03934502: Evobrutinib.

Is NCT03934502 still recruiting?

NCT03934502 is currently completed. Last updated 7 July 2020.

Last reviewed 2020-07-07 · How we verify

NCT03934502

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Meal Composition and Timing on Evobrutinib Bioavailability

Completed Phase 1 Last updated 7 July 2020

What this trial tests

Phase 1 trial testing Evobrutinib in Healthy in 20 participants. Completed in 12 June 2019.

Timeline

15 April 2019

Primary endpoint
12 June 2019

12 June 2019

Quick facts

Lead sponsor	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	other
Enrollment	20
Start date	15 April 2019
Primary completion	12 June 2019
Estimated completion	12 June 2019
Sites	1 location across Germany

Drugs / interventions tested

Evobrutinib — full drug profile →

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the Pharmacokinetics (PK) of the Phase II tablet formulation of Evobrutinib under fasted conditions, within 30 minutes after start of a light meal, one hour prior to start of a low-fat meal, and 2 hours after start of a low-fat meal.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies.
Guo X, Chen S, Wang X, Liu X. · · 2023 · cited 27× · PMID 37081866 · DOI 10.3389/fimmu.2023.1138483

Verify or expand the search:

Other trials of Evobrutinib

Trials testing the same drug.

NCT05248945 — DDI Study of Evobrutinib and Carbamazepine · Phase 1 · completed
NCT04338061 — Study of Evobrutinib in Participants With RMS (evolutionRMS 2) · Phase 3 · terminated
NCT04338022 — Study of Evobrutinib in Participants With RMS (evolutionRMS 1) · Phase 3 · terminated
NCT04314024 — Relative Bioavailability (rBA) of Evobrutinib Intended Commercial and Clinical Tablets, and Effect of Food on Intended C · Phase 1 · completed
NCT04032171 — Study of Evobrutinib in Participants With RMS · Phase 3 · terminated

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany trials

Trials by the same sponsor.

NCT07499362 — Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER) · Phase 2 · recruiting
NCT07340827 — A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH · Phase 3 · recruiting
NCT07269327 — An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin · Phase 1 · completed
NCT06806046 — Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors · Phase 1 · active not recruiting
NCT06589713 — Effect of Renal Impairment on Enpatoran Pharmacokinetics · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03934502 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Last refreshed: 7 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03934502.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing